Skip to main content
S&P 5007,718.94-1.11%DOW51,621.48-0.09%NASDAQ26,692.87-1.88%BTC$81,472.00-2.36%ETH$2,412.80-3.97%GOLD$4,129.10+0.52%OIL$95.05-0.04%
Smart Investors Daily
SID Premium
Beyond Air, Inc. logo

NASDAQ · XAIR

Beyond Air, Inc.

Healthcare · Medical - Devices

$2.19

Down-$0.09 (-4.11%)

Updated Oct 14, 2026, 10:43 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.6M
P/E ratio
-0.13
Dividend yield
0.00%
52-week range
$0.33 – $9.28
Volume
36.37K
Avg. volume
537.56K

Price performance · XAIR

XAIR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 13, 2026

XAIR closed at $2.19 after 21 trading sessions, down 30.03% for the selected period.

Last close
$2.19
Period change
-30.03%
Period low
$2.19
Period high
$3.20
Daily close
View OHLC price history
XAIR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 13, 2026$2.35$2.37$2.16$2.1936.37K
Oct 12, 2026$2.27$2.47$2.24$2.3130.21K
Oct 9, 2026$2.30$2.335$2.20$2.2565.39K
Oct 8, 2026$2.76$2.76$2.31$2.31100.04K
Oct 7, 2026$2.49$2.60$2.47$2.5436.21K
Oct 6, 2026$2.76$2.82$2.545$2.5536.48K
Oct 5, 2026$2.93$2.99$2.806$2.8443.09K
Oct 2, 2026$2.93$2.99$2.82$2.8218.17K
Oct 1, 2026$2.7121$2.93$2.6701$2.9350.78K
Sep 30, 2026$2.745$2.80$2.66$2.7638.88K
Sep 29, 2026$2.59$2.94$2.57$2.8377.19K
Sep 28, 2026$2.85$2.85$2.38$2.59156.92K
Sep 25, 2026$3.00$3.00$2.775$2.85203.23K
Sep 24, 2026$3.01$3.2099$2.85$3.17702.65K
Sep 23, 2026$3.14$3.20$3.00$3.0136.66K
Sep 22, 2026$3.15$3.20$3.05$3.2015.75K
Sep 21, 2026$3.17$3.2191$3.0878$3.1322.95K
Sep 18, 2026$3.07$3.26$3.07$3.0938.84K
Sep 17, 2026$3.13$3.18$3.08$3.0816.61K
Sep 16, 2026$3.13$3.1861$3.06$3.0820.12K
Sep 15, 2026$3.16$3.2027$3.08$3.1320.49K

Latest XAIR news

The latest Smart Investors Daily articles mentioning XAIR.

Stock researchCompany · Overview

XAIR research

Overview

Company profile and research snapshot.

Company profile

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$1.00
Implied upside
—
Analysts
11
XAIR recent ratings
DateFirmRatingTarget
Sep 1, 2026Lake StreetBuy—
Mar 27, 2026D. Boral CapitalBuy—
Mar 18, 2026D. Boral CapitalBuy—
Mar 10, 2026D. Boral CapitalBuy—
Jan 21, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Comp

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By